TRVI logo

Trevi Therapeutics, Inc. Common Stock


TRVI: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.


Show TRVI Financials

Consumer Interest
SEC Filings

Recent trades of TRVI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by TRVI's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Treatment of chronic cough, breathlessness and dyspnea May. 30, 2023
  • Patent Title: Methods for treating pruritus Mar. 26, 2019
  • Patent Title: Compounds for treating pruritic conditions Apr. 18, 2017
  • Patent Title: Methods for treating pruritus Mar. 24, 2015
  • Patent Title: Methods for treating pruritis Jan. 27, 2015
  • Patent Title: Methods for treatment of pruritis Jan. 28, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of TRVI in WallStreetBets Daily Discussion


Recent insights relating to TRVI

CNBC Recommendations

Recent picks made for TRVI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TRVI

Corporate Flights

Flights by private jets registered to TRVI